Teva nears restart of CA plant; Packaging miscommunication has big price;

> Teva expects to restart production at its Irvine, CA, plant next month, following a remediation effort prompted by a December 2009 warning letter. Story

> Life sciences artwork management firm Kallik says that human error and incomplete product data have a big effect on production; poor coordination between the creative and technical sides of the house lengthens review cycles and generates unnecessary rework. Article

> An RFID pilot for track and trace at the item, pack and pallet level has been completed by Argentinean drugmaker Laboratorios Gador. Story

> CMO ScinoPharm in Taiwan will make vilazodone hydrochloride, the active ingredient in Clinical Data's just approved antidepressant, Viibryd. Item

> High tech electronics may provide a role model for the biopharma supply chain. Column

> The U.S. Trade and Development Agency is organizing a two-week trade mission to connect Indian drug executives and officials with U.S. cold chain suppliers and manufacturers. Article

> Contract manufacturer Helix plans to begin construction of a manufacturing plant in Costa Rica. Story

> Felten has designed and built a manufacturing facility for Czech-based Lonza Biotec, boosting fermentation capacities by 50 percent. Story

Suggested Articles

Teva will produce its new migraine drug at a plant in Israel and more news of note.

The shortage of childhood cancer drug vincristine was front and center during the Senate hearing for Stephen Hahn, nominee for FDA commissioner.

The FDA has lambasted the Torrent Pharmaceuticals in a warning letter for making OTC meds using water tainted with bacteria.